NASDAQ:CHMA Chiasma (CHMA) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free CHMA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.76▼$3.7650-Day Range$3.76▼$4.7152-Week Range$2.77▼$5.74Volume147 shsAverage Volume2.12 million shsMarket Capitalization$217.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Chiasma alerts: Email Address Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About Chiasma Stock (NASDAQ:CHMA)Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Read More Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. CHMA Stock News HeadlinesOctober 29, 2023 | thestreet.comChiasma Craters on FDA Drug RejectionOctober 6, 2022 | globenewswire.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswireMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.September 28, 2022 | businesswire.comIronshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business WireSeptember 16, 2022 | marketscreener.comCHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.comSeptember 16, 2022 | streetinsider.comAmryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.comSeptember 7, 2022 | uk.finance.yahoo.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UKAugust 12, 2022 | gurufocus.comMPM ASSET MANAGEMENT LLC Buys - GuruFocus.comMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.August 4, 2022 | globenewswire.comAmryt Reports Record Q2 2022 Results - GlobeNewswireJuly 12, 2022 | businesswire.comSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Business WireJuly 12, 2022 | finance.yahoo.comSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Yahoo FinanceJune 20, 2022 | finance.yahoo.comGlobal Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo FinanceJune 18, 2022 | gurufocus.comAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - GuruFocus.comJune 16, 2022 | finance.yahoo.comAt 10.4% CAGR, Global Oral Proteins and Peptides Market Size & Share to Surpass USD 8.42 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceJune 15, 2022 | globenewswire.comThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - GlobeNewswireJune 15, 2022 | finance.yahoo.comThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - Yahoo FinanceJune 8, 2022 | finance.yahoo.comAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - Yahoo FinanceMay 13, 2022 | gurufocus.comTop 5 1st Quarter Trades of MPM ASSET MANAGEMENT LLC - GuruFocus.comMay 6, 2022 | financialpost.comAmryt Reports Record Q1 2022 Results - Financial PostMay 4, 2022 | globenewswire.comAmryt Reports Record Q1 2022 Results - GlobeNewswireMay 4, 2022 | stockhouse.com2022-05-04 | NDAQ:AMYT | Press Release | Amryt Pharma plc - StockhouseMarch 21, 2022 | benzinga.comInsights on the Oral Proteins and Peptides Global Market to 2032 - Key Drivers and Challenges - Benzinga - BenzingaMarch 16, 2022 | globenewswire.comGlobal Oral Proteins and Peptides Market to 2032 - by - GlobeNewswireMarch 11, 2022 | streetinsider.comAmryt (AMYT) Reports FY Revenues of $222.5M, Growth of 22% - StreetInsider.comMarch 9, 2022 | globenewswire.comAmryt Announces 22% growth in FY 2021 Revenues to $222.5M - GlobeNewswireFebruary 28, 2022 | prnewswire.comWarm Autoimmune Hemolytic Anemia Market is Expected to Witness Growth at an Accelerated CAGR of 14.7% in the 7MM for the Study Period 2018-30, Assesses DelveInsight - PRNewswireSee More Headlines Receive CHMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2021Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CHMA CUSIPN/A CIK1339469 Webwww.chiasmapharma.com Phone617-928-5300FaxN/AEmployees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-113.57% Return on Assets-57.62% Debt Debt-to-Equity RatioN/A Current Ratio7.91 Quick Ratio7.08 Sales & Book Value Annual Sales$1.11 million Price / Sales196.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book2.36Miscellaneous Outstanding Shares57,894,000Free FloatN/AMarket Cap$217.68 million OptionableNot Optionable Beta1.28 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Raj Kannan (Age 56)Pres, CEO & Director Comp: $827.55kMr. Anand Varadan (Age 54)Exec. VP & Chief Commercial Officer Comp: $542.27kMr. John Brendan Doyle (Age 44)Sr. VP, CFO & Treasurer Mr. Drew Enamait (Age 47)VP of Fin. & Admin. Ms. Dawn Schottlandt CFAVP of Investor Relations & Corp. CommunicationsMr. Lee G. Giguere (Age 40)VP, Gen. Counsel and Sec. Mr. Derek BrownVP of MarketingMr. Joe LyonsExec. Director of HRDr. William H. Ludlam (Age 55)Sr. VP of Clinical Devel. & Medical Affairs Mr. David M. SchubertSr. VP of Regulatory & QualityMore ExecutivesKey CompetitorsGalectin TherapeuticsNASDAQ:GALTOrganigramNASDAQ:OGIOvid TherapeuticsNASDAQ:OVIDMerrimack PharmaceuticalsNASDAQ:MACKConduit PharmaceuticalsNASDAQ:CDTView All Competitors CHMA Stock Analysis - Frequently Asked Questions How were Chiasma's earnings last quarter? Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.80 million. What other stocks do shareholders of Chiasma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals (GWPH), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL) and Ovid Therapeutics (OVID). When did Chiasma IPO? Chiasma (CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers. This page (NASDAQ:CHMA) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithCould Your Accounts Be Frozen?Allegiance GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing$5,000 Gold?Stansberry ResearchBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chiasma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
